Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Indicatori Ecografici dello Stato Nutrizionale e dei Risultati del Trattamento nei Pazienti Chirurgici in Terapia Intensiva

6 novembre 2026 aggiornato da: Osijek University Hospital

Indicatori ecografici dello stato nutrizionale e degli esiti del trattamento in pazienti chirurgici nell'unità di terapia intensiva

Ultrasound Indicators of Nutritional Status and Treatment Outcomes in Surgical Patients in the Intensive Care Unit

Panoramica dello studio

Descrizione dettagliata

The surgical intensive care unit (ICU) provides continuous preoperative and postoperative monitoring of hemodynamically unstable, critically or potentially critically ill patients whose treatment requirements exceed the scope of the competent surgical department. The most common reasons for admission to the ICU are older age, multiple comorbidities, sepsis, demanding and high-risk surgery, and complications during the procedure. The literature increasingly reports that patients' nutritional status and clinical frailty are predictors of ICU treatment duration and outcome. The nutritional status (NS) of patients in intensive care units (ICUs) is assessed using clinical and laboratory indicators, including body mass index (BMI), the clinical frailty score, and hemoglobin and albumin levels. It is quantified by rating scales such as NRS (Nutritional Risk Screening) and MUST (Malnutrition Universal Screening Tool).

Frailty syndrome is defined as a patient's reduced capacity to tolerate changes in physical, physiological, and cognitive body functions. Given the reduction in the organism's physiological reserves, the patient becomes vulnerable to stressors and acute complications associated with the health condition. Patient frailty is correlated with aging, and age is among the most important determinants of frailty. In the intensive care unit, patient frailty is an important predictor of the duration and outcome of treatment, the development of complications during hospitalization, and, as noted above, the consumption of available resources. Assessment of patient frailty enables the appropriate selection of therapeutic procedures and provides overall support to the patient, aiming to achieve optimal treatment outcomes. Patient frailty can be measured using clinical scales; the most commonly used are the Clinical Frailty Scale (CSF) and the modified frailty index (mFI).

Ultrasound is a diagnostic tool that, due to its non-invasiveness and ease of use, is increasingly used to assess the patient's condition and changes during treatment. The most commonly measured ultrasound indicators in intensive care are the presence of effusion or blood in body cavities, flow through blood vessels, and measurement of distance for puncture purposes.

Ultrasound has recently been used to assess the patient's nutritional status by measuring muscle thickness and echogenicity, most often of the upper leg muscles, such as the quadriceps. Muscle cross-sectional area and the thickness of the adipose tissue above it are often measured.

Studies on nutritional status and its relationship with muscle echogenicity in the surgical patient population are rare.

The prospective observational study will include consecutive patients of both genders admitted to the Department of Intensive Care of the Clinical Hospital Center in Osijek. The expected number of subjects is 50. The study will be conducted after approval by the ethics committee of the Clinical Hospital Center in Osijek, and before inclusion, the investigator will obtain informed consent from the patient or a guardian. Patients who have had surgery on their right leg, on which muscle thickness and echogenicity will be measured, patients for whom informed consent is not obtained, and patients who are paraplegic will not be included in the study.

Demographic data will be recorded from medical records and the hospital information system for each individual subject. Patient demographics (age, gender), comorbidities, laboratory parameters (hemoglobin, albumin, lactate), reason and duration of intensive care unit hospitalization, and time required to wean the patient from mechanical ventilation will be recorded. Patient frailty will be assessed during an interview. For patients who are unable to provide information, information will be collected from family members. For the purposes of this study, the CFS will be used, which categorizes patients from 1 (very active, physically strong) to 9 (very sick, not expected to survive more than 6 months). The examiner will perform an ultrasound examination of the thigh muscles (m. rectus femoris, m. vastus intermedius, m. vastus medialis, m. vastus lateralis) with a linear ultrasound probe for each subject within 48 hours of admission to the intensive care unit (ICU), measure the thickness of the muscle and the fatty tissue immediately above it, and display the dimensions in mm. Muscle echogenicity will be expressed numerically using image analysis. Signal intensity will be calculated in a standard 5 × 5 mm area, equal across all images, using the ImageJ/Fiji software. The average of 3 ultrasound measurements will be calculated. In addition to ultrasound measurements, laboratory indicators of the patient's nutritional status are also important. Hemoglobin and serum albumin are most often associated with nutritional status. Their values are usually reduced in patients with clinical frailty, and the finding of anemia and hypoproteinemia of varying degrees is common in people with limited mobility, malnutrition, or in people with specific nutritional deficiencies, e.g., in liver cirrhosis. The values will be compared computationally with clinical indicators such as patient frailty, hemoglobin, albumin and the patient's status assessment obtained by rating scales (CSF, NRS).

Tipo di studio

Osservativo

Iscrizione (Effettivo)

59

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Osijek, Croazia, 31000
        • Osijek University Hospital; Medical Faculty

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione di probabilità

Popolazione di studio

The study population will be randomly selected patients admitted to the intensive care unit after undergoing a surgical procedure. These surgical procedures include abdominal, neurosurgical, plastic-reconstructive, traumatological, thoracic, and maxillofacial surgeries. Patients will be included regardless of age, gender, or whether the procedure was emergency or elective.

Descrizione

Inclusion Criteria:

  • postoperative intensive care

Exclusion Criteria:

  • surgery of the right leg
  • paraplegia, tetraplegia
  • refusal of the patient/guardian to participate in the research (informed consent not signed)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Surgical patients in the intensive care unit

The prospective observational study will include consecutive patients admitted to the Department of Intensive Care of the Clinical Hospital Center in Osijek. Patients will be randomly included, regardless of age, gender, or type of surgical procedure. The study will be conducted after approval by the ethics committee of the Clinical Hospital Center in Osijek, and before inclusion, the investigator will obtain informed consent from the patient or a guardian. Patients who have had surgery on their right leg, on which muscle thickness and echogenicity will be measured, patients for whom informed consent is not obtained, and patients who are paraplegic will not be included in the study.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Clinical Frailty Scale
Lasso di tempo: Day 1 (within 24 hours from admission to the intensive care unit)

The Clinical Frailty Scale (CFS) is a 9-point clinician-judgment tool that assesses fitness-to-frailty (1=Very Fit, 9=Terminally Ill).

Day 1 (within 24 hours from admission to the intensive care unit)
Nutritional Risk Screening 2002
Lasso di tempo: Day 1

The Nutritional Risk Screening 2002 (NRS-2002) is a rapid, validated tool designed by the European Society for Clinical Nutrition and Metabolism (ESPEN) to identify hospitalized patients at risk of malnutrition and requiring nutritional support. It calculates a total score (0-7) based on impaired nutritional status, disease severity, and age (≥70 years).

Day 1
Vastus intermedius thickness
Lasso di tempo: Day 1

Vastus intermedius thickness measured by ultrasound and expressed in centimeters.

Day 1
Rectus femoris thickness
Lasso di tempo: Day 1

Rectus femoris thickness measured by ultrasound and expressed in centimeters.

Day 1
Vastus medialis thickness
Lasso di tempo: Day 1

Vastus medialis thickness measured by ultrasound and expressed in centimeters.

Day 1
Vastus lateralis thickness
Lasso di tempo: Day 1

Vastus lateralis thickness measured by ultrasound and expressed in centimeters.

Day 1
Vastus intermedius echogenicity
Lasso di tempo: Day 1

Muscle echogenicity will be analyzed using ImageJ software and expressed as the mean gray value.

Day 1
Rectus femoris echogenicity
Lasso di tempo: Day 1

Muscle echogenicity will be analyzed using ImageJ software and expressed as mean grey value.

Day 1
Vastus medialis echogenicity
Lasso di tempo: Day 1

Muscle echogenicity will be analyzed using ImageJ software and expressed as mean grey value.

Day 1
Vastus lateralis echogenicity
Lasso di tempo: Day 1

Muscle echogenicity will be analyzed using ImageJ software and expressed as the mean gray value.

Day 1
Adipose tissue thickness
Lasso di tempo: Day 1

Thickness of adipose tissue above quadriceps femoris muscle will be mesured by ultrasound and expressed in centimeters.

Day 1
Body mass index ˙(BMI)
Lasso di tempo: Perioperative

Body Mass Index (BMI) is a screening tool that estimates body fat by dividing a person's weight in kilograms by the square of their height in meters (kg/m2)

Perioperative
Length of mechanical ventilation
Lasso di tempo: One month from admission to the ICU.

Time from admission to the intensive care unit to the onset of spontaneous breathing. The time of admission to the intensive care unit is the start of mechanical ventilation. It lasts until extubation (removal of the endotracheal tube) and continuation of spontaneous breathing. It is expressed in hours.

Whether the patient is intubated again, these two ventilation times are added together.

One month from admission to the ICU.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Haemoglobin
Lasso di tempo: Day 1

Haemoglobin levels (g/L) will be measured in the blood sample.

Day 1
Albumin
Lasso di tempo: Day 1

The albumin level (g/L) will be measured in the blood sample.

Day 1
C-reactive protein (CRP)
Lasso di tempo: Perioperative

C-reactive protein (CRP) is a liver-produced protein that serves as a key biomarker of systemic inflammation, infection, and tissue damage. CRP (mg/L) will be measured in the blood sample.

Perioperative
Lactate
Lasso di tempo: Day 1

Lactate (mmol/L) is an energy source and a metabolic product produced in muscles, red blood cells, and the brain during anaerobic metabolism. It serves as a marker of tissue oxygenation, with elevated blood levels suggesting potential metabolic stress.

Day 1

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Cattedra di studio: Slavica Kvolik, prof., Osijek University Hospital; Medical Faculty Osijek

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 febbraio 2026

Completamento primario (Effettivo)

13 ottobre 2026

Completamento dello studio (Effettivo)

6 novembre 2026

Date di iscrizione allo studio

Primo inviato

9 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 marzo 2026

Primo Inserito (Effettivo)

16 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • R1-13343

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Yes, upon request sent to principal investigator

Periodo di condivisione IPD

After study publication.

Criteri di accesso alla condivisione IPD

Upon the reasonable request sent to principal investigator.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi